These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8619916)

  • 21. Clonal analysis of murine B cell response to the human immunodeficiency virus type 1 (HIV1)-gag p17 and p25 antigens.
    Robert-Hebmann V; Emiliani S; Jean F; Resnicoff M; Traincard F; Devaux C
    Mol Immunol; 1992 Jun; 29(6):729-38. PubMed ID: 1376412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant.
    Becker PD; Fiorentini S; Link C; Tosti G; Ebensen T; Caruso A; Guzmán CA
    Vaccine; 2006 Jun; 24(25):5269-76. PubMed ID: 16713032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 p17 and IFN-gamma both induce fructose 1,6-bisphosphatase.
    Besançon F; Just J; Bourgeade MF; Van Weyenbergh J; Solomon D; Guillozo H; Wietzerbin J; Cayre YE
    J Interferon Cytokine Res; 1997 Aug; 17(8):461-7. PubMed ID: 9282826
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-function studies of the human immunodeficiency virus type 1 matrix protein, p17.
    Cannon PM; Matthews S; Clark N; Byles ED; Iourin O; Hockley DJ; Kingsman SM; Kingsman AJ
    J Virol; 1997 May; 71(5):3474-83. PubMed ID: 9094619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens.
    Fiorentini S; Becker PD; Marini E; Marconi P; Avolio M; Tosti G; Link C; Manservigi R; Guzman CA; Caruso A
    Viral Immunol; 2006; 19(2):177-88. PubMed ID: 16817760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines.
    Vitale M; Caruso A; De Francesco MA; Rodella L; Bozzo L; Garrafa E; Grassi M; Gobbi G; Cacchioli A; Fiorentini S
    Br J Haematol; 2003 Jan; 120(2):337-43. PubMed ID: 12542496
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
    Ota A; Tanaka-Taya K; Ueda S
    Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
    Tewari D; Notkins AL; Zhou P
    J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-dimensional structure of the human immunodeficiency virus type 1 matrix protein.
    Massiah MA; Starich MR; Paschall C; Summers MF; Christensen AM; Sundquist WI
    J Mol Biol; 1994 Nov; 244(2):198-223. PubMed ID: 7966331
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-HIV-1 p17 antibody as anti-HIV agent].
    Tsuchie H; Tochikura A; Kageyama S; Kurimura T
    Nihon Rinsho; 1993 Sep; 51 Suppl():213-8. PubMed ID: 8271386
    [No Abstract]   [Full Text] [Related]  

  • 31. Epitope mapping of a monoclonal antibody which binds HIV-1 Gag and not the Gag-derived proteins.
    Sarubbi E; Denaro M
    FEBS Lett; 1993 Dec; 335(3):335-7. PubMed ID: 7505237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa.
    Masemola AM; Mashishi TN; Khoury G; Bredell H; Paximadis M; Mathebula T; Barkhan D; Puren A; Vardas E; Colvin M; Zijenah L; Katzenstein D; Musonda R; Allen S; Kumwenda N; Taha T; Gray G; McIntyre J; Karim SA; Sheppard HW; Gray CM;
    J Immunol; 2004 Oct; 173(7):4607-17. PubMed ID: 15383595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular dynamics analysis of HIV-1 matrix protein: clarifying differences between crystallographic and solution structures.
    Verli H; Calazans A; Brindeiro R; Tanuri A; Guimarães JA
    J Mol Graph Model; 2007 Jul; 26(1):62-8. PubMed ID: 17067836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
    J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single amino acid changes in the human immunodeficiency virus type 1 matrix protein block virus particle production.
    Freed EO; Orenstein JM; Buckler-White AJ; Martin MA
    J Virol; 1994 Aug; 68(8):5311-20. PubMed ID: 8035531
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
    Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
    Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p17 and p17-containing gag precursors of input human immunodeficiency virus are transported into the nuclei of infected cells.
    Sharova N; Bukrinskaya A
    AIDS Res Hum Retroviruses; 1991 Mar; 7(3):303-6. PubMed ID: 2064827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV p17 reverses the anti-inflammatory activity of IL-4 on IL-15 stimulated monocytes and modulates their ability to secrete MIP-1 alpha.
    De Francesco MA; Poiesi C; Ricotta D; Manca N
    Virus Res; 2006 Jun; 118(1-2):170-7. PubMed ID: 16427155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-P30-52 monoclonal antibody cross-reacted to Env V3 and inhibited the viral multiplication of HIV-1-infected MT-4 cells.
    Ota A; Bautista AN; Yadav ML; Ueda S
    Hybridoma; 1999 Apr; 18(2):139-47. PubMed ID: 10380013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disappearance of anti-p17 correlates with successful isolation of human immunodeficiency virus and deterioration in clinical status.
    Kageyama S; Kurimura T
    Int J STD AIDS; 1990 Mar; 1(2):129-31. PubMed ID: 2092788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.